2023
DOI: 10.1002/eji.202250186
|View full text |Cite
|
Sign up to set email alerts
|

Tyrosine kinase inhibitor cabozantinib impacts dendritic and natural killer cells immune response in C38 syngeneic tumor model

Abstract: Tyrosine kinase inhibitor cabozantinib impacts dendritic and natural killer cells immune response in C38 syngeneic tumor modelCabozantinib is a tyrosine kinase inhibitor approved for use in all patients with metastatic renal cell carcinoma (mRCC). Its main target is VEGFR-2 conferring its strong anti-angiogenetic properties. Beside its role in aberrant angiogenesis during tumor growth, VEGF has also been described to be implicated in the accumulation of myeloid-derived suppressor cells (MDSC) in the tumor [1].… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 9 publications
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?